Methylenedioxymethoxyethylamphetamine

Last updated
Methylenedioxymethoxyethylamphetamine
MDMEOET.svg
Names
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-(2-methoxyethyl)propan-2-amine
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C13H19NO3/c1-10(14-5-6-15-2)7-11-3-4-12-13(8-11)17-9-16-12/h3-4,8,10,14H,5-7,9H2,1-2H3 X mark.svgN
    Key: LOZJEWOZOKSOKA-UHFFFAOYSA-N X mark.svgN
  • InChI=1/C13H19NO3/c1-10(14-5-6-15-2)7-11-3-4-12-13(8-11)17-9-16-12/h3-4,8,10,14H,5-7,9H2,1-2H3
    Key: LOZJEWOZOKSOKA-UHFFFAOYAB
  • CC(Cc1ccc2c(c1)OCO2)NCCOC
Properties
C13H19NO3
Molar mass 237.295 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

MDMEOET, also known as 3,4-methylenedioxy-N-methoxyethylamphetamine, is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N-methoxyethyl analogue of MDA. MDMEOET was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved) , the minimum dosage is listed as 180 mg. MDMEOET produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMEOET.

Contents

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act. [1]

See also

References

  1. ↑ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.